{"type":"trials","record":{"id":41365,"source_id":"clinicaltrials-gov","external_id":"NCT05984927","title":"NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration","brief_summary":"This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).","overall_status":"Active Not Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Elisigen, Inc.","enrollment":20,"countries":["United States","Canada"],"start_date":"2023-09-08","completion_date":"2030-01-01","last_update_date":"2026-09-10","source_url":"https://clinicaltrials.gov/study/NCT05984927","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 89 Years","comparator":null,"organization":"Elisigen, Inc.","interventions":["NG101 AAV gene therapy"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Adverse Events — From Day 0 (pre-treatment) through Week 24","Ocular and Non -Ocular Adverse Events after week 24 — From Day 0 (pre-treatment) and through Weeks 52, 104, 156, 208 an…","Systemic Immunogenic Response — From Day -14 to Weeks 4, 8, 12, 24, 52, and 104","Systemic Immunogenic Response — From Day -14 to Weeks 4, 12, and 104","Systemic Immunogenic Response — From Day -14 to Day 7, and Weeks 2, 4, and week 12.","Systemic Immunogenic Response — From Day 0 (pre-treatment) to Weeks 24, 52, and 104","Signs of CNV (choroidal neovascularization) Activity — From Day -7 to Weeks 8, 24, 52, and 104","Central Subfield Thickness (CST) — From Day -7 to Weeks 24, 52, 104, 156, 208, and 260","Best Corrected Visual Acuity (BCVA) — From Day -7 to Weeks 24, 52, 104, 156, 208 and 260","Cumulative Number of Rescue Therapy Injections — Through Weeks 24, 52, 104, 156, 208, and 260"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","NG101 AAV gene therapy"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05984927","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-09-08 to 2030-01-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 89 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.799Z","intervention":["NG101 AAV gene therapy"],"participants":20,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Adverse Events — From Day 0 (pre-treatment) through Week 24","Ocular and Non -Ocular Adverse Events after week 24 — From Day 0 (pre-treatment) and through Weeks 52, 104, 156, 208 an…","Systemic Immunogenic Response — From Day -14 to Weeks 4, 8, 12, 24, 52, and 104","Systemic Immunogenic Response — From Day -14 to Weeks 4, 12, and 104","Systemic Immunogenic Response — From Day -14 to Day 7, and Weeks 2, 4, and week 12.","Systemic Immunogenic Response — From Day 0 (pre-treatment) to Weeks 24, 52, and 104","Signs of CNV (choroidal neovascularization) Activity — From Day -7 to Weeks 8, 24, 52, and 104","Central Subfield Thickness (CST) — From Day -7 to Weeks 24, 52, 104, 156, 208, and 260","Best Corrected Visual Acuity (BCVA) — From Day -7 to Weeks 24, 52, 104, 156, 208 and 260","Cumulative Number of Rescue Therapy Injections — Through Weeks 24, 52, 104, 156, 208, and 260"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41365","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}